In lung squamous cell carcinoma, the low YTHDF1 group was also mainly enriched in immunity-related signaling pathways (allograft rejection, IL2-STAT5 signaling, inflammatory response, IL6-JAK-STAT3 signaling, and TNFA signaling via NFKB and interferon gamma response). The gene discussed is IL2; the disease is squamous cell lung carcinoma.